The opinion piece argues that New Jersey's gubernatorial candidates, Mikie Sherrill and Jack Ciattarelli, are ignoring the state's significant legal cannabis economy and its voters. The 2020 legalization referendum showed broad support for cannabis. While Sherrill supports legalization and pro-cannabis measures, Ciattarelli has softened his previous opposition, now supporting medical cannabis home cultivation but not adult personal cultivation. The article highlights that the cannabis market is rapidly growing, potentially surpassing traditional farming as the state's third-largest market. Cannabis consumers are a powerful voting bloc and have specific issues the next governor needs to address, including the neglected medical program, high product prices, and the ban on personal cultivation. < Back Op-Ed: New Jersey Governor Candidates Must Do More for Cannabis Consumers Oct 23, 2025 Source: Marijuana Moment Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link New Jersey is in the middle of a major cannabis-driven economic boom, but the leading gubernatorial candidates, Mikie Sherrill and Jack Ciattarelli, seem to be keeping the community at arm's length. Despite the industry raking in over $1 billion and potentially becoming the state's third-largest market, voters feel the candidates aren't doing enough to address high prices and the ongoing ban on home cultivation. Sherrill has recently warmed up to the idea of personal growing, while Ciattarelli has only gone as far as supporting it for medical patients. This matters to everyday tokers because the next governor will hold the keys to lower taxes and better regulations. New Jersey's enthusiasts are a massive, tax-paying voting bloc that helped pass legalization with a 67% majority. By pushing for home grow and a more robust medical program, the community can ensure that legal weed is actually affordable and accessible for everyone. It’s a clear sign that if we want better vibes and cheaper buds, we have to make our voices heard at the ballot box. < Previous Next > Recent Reviews Cookies & Alt Sol "Ridgeline Lantz" Strain Review - Takoma Wellness Center Ridgeline Lantz, cultivated by Alt Sol and currently available at Takoma Wellness Center, exudes an impressive pedigree. With its origins... Watermelon Sugar, High: Fade Co.'s Live Resin Gummies Reviewed There's a running joke about Harry Styles' summer smash that the man himself has cheerfully leaned into: nobody is entirely sure what "watermelon sugar" is, only that it sounds fantastic and you want more of it. Fade Co. seems to have taken that ambiguity as a design brief. Their new live resin gummies don't just borrow the fruit - they capture the whole breezy, sun-warmed, slightly-too-good-to-analyze feeling the song trades in, then pack it ten to a tin... Platinum TK - Green Theory Dispensary Platinum TK is an indica-dominant hybrid from the skilled cultivators at Alt Sol that offers a robust and relaxing experience. Currently... 1 2 3 4 5

Everything about Tropical Sherbert #71: effects, typical THC, lineage, and terpenes — plus hands-on product reviews and bud photos from Toker's Guide's DMV experts. < Back Tropical Sherbert #71 Strain Review Type Hybrid THC % 21% Dominant Terpene Energy NA Unknown Overview Tropical Sherbert #71 is a vibrant hybrid cannabis strain celebrated for its refreshing fruit profile and balanced effects. Created through a lineage of high-quality "Sherbet" genetics, it is sought after by those looking for a flavorful, mood-boosting experience that combines physical ease with mental clarity. Effects Tropical Sherbert #71 is an energizing hybrid strain that provides an immediate cerebral lift, fostering happiness, positivity, and a boost in creativity. Its high energy and focus make it an ideal choice for daytime activities, social gatherings, or outdoor exercise like hiking. As the experience progresses, it transitions into a calming physical relaxation that eases tension and dissipates anxiety without the heavy sedation of "couch-lock." This strain is particularly effective for managing mood-related issues and stress, while also providing gentle relief for physical discomfort. Its complex terpene profile is led by limonene, which drives its mood-elevating citrus notes, supported by myrcene for herbal sweetness and relaxation, and caryophyllene, which offers potential anti-inflammatory benefits. Together, these elements make Tropical Sherbert #71 a functional and uplifting option for those seeking mental clarity and physical ease. Positive Effects Side Effects Common Uses Relaxed 0% Happy 0% Euphoric 0% Uplifted 0% Talkative 0% Creative 0% Energetic 0% Focused 0% Giggly 0% Tingly 0% Hungry 0% Sleepy 0% Unknown Dry Mouth 0% Dry Eyes 0% Dizzy 0% Paranoid 0% Anxious 0% Hungry 0% Tingly 0% Sleepy 0% Appearance The buds of Tropical Sherbert \#71 are typically soft, fluffy, and oversized. They exhibit a forest-green base with bright undertones, accented by a dense coating of thin orange pistils. A frosty layer of tiny white trichomes covers the surface, giving the nugs a shimmering, resinous look. Aroma This strain features a vibrant and complex scent profile dominated by sour citrus and lemon overtones. These sharp notes are balanced by a background of fresh tropical fruits and a smooth, creamy vanilla finish, creating an inviting and tropical olfactory experience. Flavor The taste mirrors its aromatic profile, offering a sweet and creamy vanilla sherbet flavor on the inhale. This is followed by a medley of tropical fruit notes and a lingering, tangy citrus exhale that is smooth and pleasant. Lineage Tropical Sherbert \#71 is a phenotype resulting from the cross between Tropical Sunset and the classic Sherbet (often referred to as Sunset Sherbert). This genetic pairing blends the exotic fruitiness of its parents with a well-rounded hybrid structure. Terpene Profile - Limonene: Provides the prominent citrus and lemon notes while contributing to mood elevation. - Myrcene: Adds a touch of herbal sweetness and supports physical relaxation. - Caryophyllene: Offers subtle spicy undertones and potential anti-inflammatory benefits.Effects Users report an immediate cerebral lift that brings about a sense of happiness, positivity, and creativity. It is highly energizing and focused, making it suitable for daytime activities or hiking. As the high progresses, a calming physical relaxation sets in that numbs tension without causing heavy sedation or "couch-lock," often leaving users feeling blissful and occasionally aroused. Cultivation Preferences - Flowering Time: Approximately 8 to 9 weeks indoors. - Harvest: Early October for outdoor growers. - Characteristics: The strain is generally considered easy to grow and is known for producing resinous, visually appealing buds.Origin While its parentage includes the San Francisco-born Sunset Sherbert, Tropical Sherbert \#71 has been popularized by various breeders and brands across the North American market, particularly within the West Coast and Northwest craft cannabis scenes. Seed Suppliers Genetics and seeds for this lineage can often be found through specialized suppliers like High Supply (Cresco), and various boutique seed banks that carry Sherbinskis-descended phenotypes. Conclusion Tropical Sherbert \#71 is an excellent choice for consumers who prioritize a dessert-like flavor profile and a functional, happy high. Its ability to dissipate anxiety and spark energy makes it a standout option for social gatherings or active daytime use. Previous Next

This study aims to update data on patient outcomes within the state's medical cannabis program. < Back Georgia is Checking in with Patients to See How Medical Herb is Really Helping Apr 16, 2026 Source: Staff Cannabis Business Times Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Big things are happening in the Peach State! Georgia has just kicked off a massive statewide research initiative for 2026, and it is all about listening to the people who matter most: the patients. For a long time, Georgia’s medical cannabis scene has been known for its strict limits and narrow focus, but this new study is looking to change that by gathering real-world evidence directly from those navigating the system. Instead of just looking at spreadsheets or legal jargon, researchers are diving deep into how this medicine actually affects daily life. They want to know what’s working, what isn't, and how these restricted products are helping folks manage their specific conditions. This is a huge deal for the community because it moves the conversation away from politics and toward actual human wellness. When lawmakers have access to solid data showing that cannabis is improving lives, it becomes much easier to argue for expanded access, better product variety, and higher THC caps. For local enthusiasts and patients, this news is a breath of fresh air. It signals that the state is finally ready to treat cannabis as a legitimate therapeutic tool rather than a legal loophole. If you’re a cardholder in Georgia, keep an eye out for opportunities to participate in surveys or polls. Your feedback is the fuel that drives policy change. Sharing your experience helps build a bridge between the current restrictive laws and a more accessible, patient-first future. The takeaway here is simple: your voice has power. By documenting these outcomes, Georgia is laying the groundwork for a more robust and compassionate program. Whether you use cannabis for chronic pain, PTSD, or other qualifying conditions, this study is a major step toward a world where your needs are prioritized. It’s an exciting time to see the industry evolve, and we’re one step closer to making high-quality cannabis accessible to everyone who needs it in the South. < Previous Next > Recent Reviews Cookies & Alt Sol "Ridgeline Lantz" Strain Review - Takoma Wellness Center Ridgeline Lantz, cultivated by Alt Sol and currently available at Takoma Wellness Center, exudes an impressive pedigree. With its origins... Watermelon Sugar, High: Fade Co.'s Live Resin Gummies Reviewed There's a running joke about Harry Styles' summer smash that the man himself has cheerfully leaned into: nobody is entirely sure what "watermelon sugar" is, only that it sounds fantastic and you want more of it. Fade Co. seems to have taken that ambiguity as a design brief. Their new live resin gummies don't just borrow the fruit - they capture the whole breezy, sun-warmed, slightly-too-good-to-analyze feeling the song trades in, then pack it ten to a tin... Platinum TK - Green Theory Dispensary Platinum TK is an indica-dominant hybrid from the skilled cultivators at Alt Sol that offers a robust and relaxing experience. Currently... 1 2 3 4 5

Welcome to the June 2025 horoscopes! Read this month's column & discover the strain that best matches this month's movements. The post Star signs and cannabis strains: June 2025 horoscopes appeared first on Leafly. < Back Star signs and cannabis strains: June 2025 horoscopes May 30, 2025 Source: Carmen Ramirez Leafly Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Welcome to the June 2025 horoscopes! Read this month's column & discover the strain that best matches this month's movements. The post Star signs and cannabis strains: June 2025 horoscopes appeared first on Leafly. < Previous Next > Recent Reviews Cookies & Alt Sol "Ridgeline Lantz" Strain Review - Takoma Wellness Center Ridgeline Lantz, cultivated by Alt Sol and currently available at Takoma Wellness Center, exudes an impressive pedigree. With its origins... Watermelon Sugar, High: Fade Co.'s Live Resin Gummies Reviewed There's a running joke about Harry Styles' summer smash that the man himself has cheerfully leaned into: nobody is entirely sure what "watermelon sugar" is, only that it sounds fantastic and you want more of it. Fade Co. seems to have taken that ambiguity as a design brief. Their new live resin gummies don't just borrow the fruit - they capture the whole breezy, sun-warmed, slightly-too-good-to-analyze feeling the song trades in, then pack it ten to a tin... Platinum TK - Green Theory Dispensary Platinum TK is an indica-dominant hybrid from the skilled cultivators at Alt Sol that offers a robust and relaxing experience. Currently... 1 2 3 4 5

The firing of Attorney General Pam Bondi is not expected to delay the rescheduling of marijuana to Schedule 3 of the Controlled Substances Act despite Justice Department turmoil. < Back No Buzzkill in D.C.: Federal Shake-ups Won't Stall the Shift to Schedule III Apr 2, 2026 Source: Chris Roberts MJbizDaily Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link If you have been keeping an eye on the news lately, you might have felt a bit of a buzzkill seeing the headlines about the latest shake-up in the Justice Department. Attorney General Pam Bondi, who was specifically tasked with overseeing the federal rescheduling of cannabis, was suddenly let go by the administration. Whenever a key player in the legal game gets benched, it is natural to worry that all the hard-earned progress we have been making might suddenly grind to a halt. However, there is no need to stress or put your celebration on hold just yet. Despite the high-level personnel changes and the general sense of turmoil in D.C., the consensus among those in the know is that the move to Schedule 3 is still full steam ahead. This transition is much bigger than any one person in the cabinet. The momentum for reclassifying marijuana is backed by significant administrative work and a growing national demand for sensible drug policy that reflects the reality of 2026. For the everyday toker, this is actually a very positive sign of resilience. It shows that the path toward federal recognition of the medical value of cannabis is becoming more solidified and less dependent on individual political appointments. When the plant finally moves to Schedule 3, it opens doors for more legitimate research, better banking for the shops we love, and a general reduction in the stigma that has followed the community for decades. Our advice? Do not let the political noise distract you from the bigger picture. The bureaucratic process for rescheduling is a slow-moving beast, but it is still moving in the right direction. While we wait for the final paperwork to clear, keep supporting your local craft growers and budtenders. They are the ones doing the real work on the ground while the politicians play musical chairs. Stay informed, stay positive, and rest easy knowing that the green wave is not being pulled back by this latest bit of D.C. drama. < Previous Next > Recent Reviews Cookies & Alt Sol "Ridgeline Lantz" Strain Review - Takoma Wellness Center Ridgeline Lantz, cultivated by Alt Sol and currently available at Takoma Wellness Center, exudes an impressive pedigree. With its origins... Watermelon Sugar, High: Fade Co.'s Live Resin Gummies Reviewed There's a running joke about Harry Styles' summer smash that the man himself has cheerfully leaned into: nobody is entirely sure what "watermelon sugar" is, only that it sounds fantastic and you want more of it. Fade Co. seems to have taken that ambiguity as a design brief. Their new live resin gummies don't just borrow the fruit - they capture the whole breezy, sun-warmed, slightly-too-good-to-analyze feeling the song trades in, then pack it ten to a tin... Platinum TK - Green Theory Dispensary Platinum TK is an indica-dominant hybrid from the skilled cultivators at Alt Sol that offers a robust and relaxing experience. Currently... 1 2 3 4 5

The Michigan Court of Claims heard arguments concerning the constitutionality of a new 24% wholesale tax on cannabis products. < Back Michigan cannabis industry fights massive tax hike in court Nov 26, 2025 Source: Margaret Jackson MJbizDaily Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The Michigan Court of Claims heard arguments Tuesday over the constitutionality of a new 24% wholesale tax on cannabis products. Michigan cannabis industry fights massive tax hike in court is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs < Previous Next > Recent Reviews Cookies & Alt Sol "Ridgeline Lantz" Strain Review - Takoma Wellness Center Ridgeline Lantz, cultivated by Alt Sol and currently available at Takoma Wellness Center, exudes an impressive pedigree. With its origins... Watermelon Sugar, High: Fade Co.'s Live Resin Gummies Reviewed There's a running joke about Harry Styles' summer smash that the man himself has cheerfully leaned into: nobody is entirely sure what "watermelon sugar" is, only that it sounds fantastic and you want more of it. Fade Co. seems to have taken that ambiguity as a design brief. Their new live resin gummies don't just borrow the fruit - they capture the whole breezy, sun-warmed, slightly-too-good-to-analyze feeling the song trades in, then pack it ten to a tin... Platinum TK - Green Theory Dispensary Platinum TK is an indica-dominant hybrid from the skilled cultivators at Alt Sol that offers a robust and relaxing experience. Currently... 1 2 3 4 5

The global cannabis industry is moving towards harmonized medical regulations and pharmaceutical-grade standards, while the U.S. remains fragmented, risking being sidelined in international trade. The Global Cannabis Regulatory Summit highlighted the need for unified global standards. Europe is leading in regulatory momentum with medical markets expanding and requiring pharma-grade protocols. U.S. rescheduling of cannabis to Schedule III could encourage investment but won't immediately open international trade for state-legal operators due to DEA restrictions. Experts advise U.S. operators to align with GMP standards and build international partnerships to prepare for future global integration. < Back Global Cannabis Playbook Emerges Amid U.S. Uncertainty Sep 24, 2025 Source: Pam Chmiel MG Magazine Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link While international markets move steadily toward harmonized medical cannabis regulations, the United States remains mired in uncertainty. Without federal reform, U.S. operators risk being sidelined just as the groundwork for a global industry is being laid. Other countries are advancing with pharmaceutical-grade standards and unified frameworks, while the U.S. clings to a patchwork, recreational-first approach that may not meet international requirements. The question now is whether America can adapt quickly enough to join the conversation or be consigned to watching from the sidelines as others set the rules. Adding to the complexity, U.S. cannabis companies are up against global competitors with access to lower-cost labor, better cultivation climates, and more advanced infrastructure. All of this puts U.S.-based consumer packaged goods (CPG) brands hoping to compete globally at a disadvantage. Although the U.S. has the potential to lead in cannabinoid science and therapeutic development, the country risks being left behind in the global market. The disconnect between U.S. and international markets was a key topic at the inaugural Global Cannabis Regulatory Summit in Washington, D.C. — a landmark event that brought together regulatory, medical, and trade officials from seventeen countries. The summit marked the first coordinated international effort to align standards and set the groundwork for a unified global industry. Spearheaded and funded by Will Muecke and Stanton McLean, partners at London-based investment firm Artemis Growth Partners, the summit also focused on discouraging Europe from replicating the U.S.’s fragmented regulatory model. “It became very apparent that where we are in the cannabis cycle in Europe could easily turn into the U.S.’s fragmented system,” said Muecke, who — thanks to an Artemis office in San Jose, California — has watched the industry develop on both sides of the Atlantic. “We’re at a change point. We need a playbook of concrete steps to get to what we think is a very robust medical market.” He emphasized adult-use legalization in Europe depends on first ensuring a healthy medical industry. “If medical fails, then we’ll never get to adult use,” he said. “And I think right now we all see medical as a huge success.” To drive global cohesion, Artemis convened an invite-only group of regulators and policy leaders from the United Nations, European Union trade groups, U.S. state agencies, and international standards bodies including ASTM International, United States Pharmacopeia (USP), and the International Organization for Standardization (ISO). According to Muecke, the goal is to establish a permanent institution representing the entire global supply chain and serving as a trusted point of contact for regulators worldwide. “We hope to create a single, authoritative body regulators can engage with, whether that’s the INCB [International Narcotics Control Board], EU health ministries, or U.S. federal agencies once reform happens,” he said. “The current ‘walled garden’ approach in the U.S. won’t work on a global scale.” The shifting international landscape Despite a growing international reform movement, the global cannabis industry remains highly fragmented. Regions are progressing at markedly different speeds in terms of regulation and market development. In North America, for example, Canadian operators are expanding abroad because they’re facing flat domestic sales. At the same time, U.S. multistate operators (MSOs) remain boxed in by high taxes, limited capital access, and a continuing federal ban on interstate and international commerce. With medical markets expanding across twenty-one EU member states, Europe currently leads in regulatory momentum. Germany’s landmark legislation in April 2024 set the tone. Pilot programs in the Netherlands, Switzerland, and the UK are testing different models, with France and Greece preparing to scale up. However, progress in countries like Spain, Portugal, and Poland has slowed. In Latin America, exports are the primary focus. Colombia has emerged as a global leader in genetics and bulk supply. Brazil is steadily broadening medical access and easing penalties for personal use, but political and legal uncertainty continue to stymie Mexico’s potential. Oceania’s medical markets, particularly in Australia and New Zealand, are thriving, though regulatory scrutiny is increasing. Africa is still in the early stages of development; South Africa has legalized home cultivation, and Morocco is building out its infrastructure to support medical exports. Asia remains the most conservative region. Thailand recently backtracked on its adult-use legalization and is redesigning its regulatory framework, while Japan is cautiously expanding medical cannabis and CBD access under strict controls. International frameworks take shape In 2020, the World Health Organization (WHO) and United Nations took a landmark step by removing cannabis from Schedule IV of the Single Convention on Narcotic Drugs. The category is reserved for substances deemed to have little or no medical value. Althought the move didn’t legalize the plant globally or lift existing restrictions in member countries, rescheduling acknowledged the plant’s therapeutic potential and opened the door for expanded medical research and regulatory reform. At the heart of international enforcement is the INCB, one of four key bodies tasked with overseeing compliance with global drug-control treaties. Alongside the Commission on Narcotic Drugs, the WHO, and the UN Secretary-General, whose drug-related functions are carried out by the UN Office on Drugs and Crime, the INCB monitors adherence to the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 UN Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Despite growing public support and scientific validation of cannabis’s medical uses, enforcement remains complicated by a fragmented global legal landscape. Countries like Canada and Germany have adopted progressive regulatory frameworks, while others maintain a strict interpretation of international treaties. The patchwork presents challenges for the INCB as it navigates the tension between treaty compliance and national policy shifts driven by research, patient needs, political expediency, and consumer demand. Pharma-grade standards set the course The playbook by which a global industry will operate already is being written in Europe and other regions that are developing medical-first markets. The vast majority of these markets require pharmaceutical-grade protocols, including EU Good Manufacturing Practices (EU-GMP) and Good Agricultural and Collection Practices (GACP), as well as pharmaceutical-level laboratory testing. Cannabis medicines in Europe must meet the same stringent standards as other controlled substances under the UN’s Single Convention on Narcotic Drugs and national medicines acts. This means all producers of cannabis products must prove consistent chemical composition, define dosage forms, and verify efficacy. Lisbon-based Somai Pharmaceuticals is among the manufacturers with international aspirations who’ve surmounted the challenges. The company produces EU-GMP-compliant products in accordance with the EU’s herbal medicine pharmacopoeia and currently operates in twelve countries, with plans to expand to eighteen by the end of 2025. Under EU law, all herbal medicinal products must obtain marketing authorization before export, be evaluated by the European Medicines Agency, and be approved by the European Commission. Once authorized, products may be distributed in any EU nation that has legalized cannabis. “It takes roughly two and a half years to get through validation, batches, stability testing, and then regulatory approval for sales to multiple markets,” said Somai Chief Executive Officer Michael Sassano. “Without it, you can’t export to other countries.” Sita Schubert, Secretary General of the European Medicinal Cannabis Association and a leading voice on regulatory policy, sees this pharma-grade model as the foundation for the industry’s future in Europe. “The EU’s requirement for herbal medicines to have market authorization validates product quality, because it fulfills the EU-GMP standards. But the final part — clinical trials and proven efficacy for a specific indication — is still missing,” she said. Whether or not a company plans to develop a full pharmaceutical product, Schubert advises all operators to adopt rigorous standards from the outset. “For Americans thinking about entering the European market, you need to understand that we are a medical market. You need to think like pharma and act like pharma,” she said. Her message is clear: Companies must shed the U.S.’s “recreational mindset” and align with strict regulatory expectations to compete globally. Muecke also pointed to Germany as a model for what a functioning medical market should look like, including providing a legal pathway for developing and commercializing cannabinoid-based medicines. “If you were to create a cannabinoid medicine in Germany, you’d have a legal market to sell it into,” he said. “There’s no innovation in the U.S. on the medical side, because you have no way of selling a finished product.” Muecke believes moving the plant to Schedule III under the U.S. Controlled Substances Act could change that, giving pharmaceutical companies the green light to invest in cannabinoid drug development. As the law stands now, with cannabis planted on Schedule I alongside illegal drugs like heroin, opium, and fentanyl, there’s no incentive for American pharma companies to invest in developing new cannabinoid medications. Muecke estimates the opportunity represented by rescheduling could unlock a $100-billion global pharmaceutical segment driven by cannabinoid formulations. He and others argue that establishing and adhering to GMP-level standards isn’t about merely compliance; it’s also about building products that benefit both medical patients and recreational consumers. As the global market moves toward standardized quality and safety benchmarks, the U.S. risks being left behind. With no national requirement for GMP compliance, American brands may find themselves struggling to adapt when international trade barriers begin to lift. “How will the U.S. compete against markets delivering consistent, safe, pharmaceutical-grade products?” Muecke asked. “Because that’s what GMP means.” Standards bodies chart the path forward Mueuke identified ASTM International as “the tip of the spear” in pushing the industry toward pharmaceutical-grade standards. Together with ISO, ASTM is helping lay the groundwork for a globally interoperable system. Standardization begins at the plant level, spanning breeding, cultivation, manufacturing, dosage, and data collection. At the moment, ASTM is the only global organization with a working group devoted to developing performance and product safety standards for cannabis. Its Committee D37 on Cannabis has published more than sixty standards, with at least thirteen U.S. states adopting or referencing those standards in their regulatory frameworks. But significant gaps remain. “While the organization is a leading voice, there’s still a need for a central global body to coordinate just cannabis,” said David Vaillencourt, vice chairman of ASTM’s D37 committee. He noted a shortage of qualified technical experts across multiple domains as one hurdle to creating a set of unified standards. “We need pharmacists to help with dosing protocols for medical cannabis, hardware engineers for vaporizer standards, and toxicologists for evaluating formulations,” he said. Though thirty countries participate in ASTM standards-setting, representation from key scientific and regulatory voices remains limited. Vaillencourt also pointed to a critical disconnect between the cannabis industry and UN voting members and treaty experts familiar with the Single Convention on Narcotic Drugs. “That’s one of the last links to unify the global industry,” he said. “But many [experts and policymakers] have been reluctant to engage due to political sensitivity.” He applauded the Artemis team for bridging that divide by establishing a summit that attained buy-in from not only regulators, but also law enforcement. “Bringing two former members of the Bureau of International Narcotics and Law Enforcement to the Global Cannabis Regulatory Summit was a huge step forward,” Vaillencourt said. “It finally got the conversation going at a serious international level.” States begin looking beyond borders The Cannabis Regulators Association (CANNRA) is a nonpartisan, international association comprising government agencies that oversee cannabis and hemp regulation across more than forty-five U.S. states and territories, as well as four additional countries: Canada, the Netherlands, Malta, and Albania. While most members focus on implementing and enforcing policy in their own jurisdictions, conversations increasingly turn toward what international commerce may require. “This is still a nascent policy area, so state regulators are largely focused on making things work in their respective states,” said CANNRA Executive Director Gillian Schauer, PhD, MPH. “But we do have conversations about how regulations need to evolve for interstate commerce in the U.S. and how global trade may eventually impact regulations as well.” Schauer anticipates continued variation across state and national regulatory frameworks but stressed the importance of establishing shared minimum standards to ensure product safety and consumer protection. She pointed out the conversation is already underway in the hemp cannabinoid space, where interstate and even international commerce is quite lively. “The key is determining how individual governments can ensure products from other jurisdictions comply with their regulations,” she explained. “This could involve specific licensing and registration requirements, third-party certification programs that verify adherence to specific standards, or intergovernmental agreements that recognize certain jurisdictions as compliant. Or, it could mean a combination of all three.” Eventually, regulators will need to tackle deeper questions. How can regulatory systems effectively communicate across borders to support tracking and compliance? What parts of the supply chain are best suited for management at the local, state, or international level? “We’re not there yet in the U.S.,” Schauer admitted. “The state-by-state infrastructure was born out of necessity as states experimented with legalization in the absence of federal reform. That makes it difficult for states to think much beyond the task at hand in their own jurisdiction.” Will rescheduling change the game? According to attorney Jason Adelstone, who specializes in cannabis and international law at Harris Sliwoski LLP, rescheduling cannabis from Schedule I to Schedule III in the U.S. will do little, at least initially, to unlock international trade. “Not much will change as far as international trade goes because, still, only DEA registrants will be permitted to export and import marijuana,” he said, referring to the U.S. Drug Enforcement Administration. “State-legal operators will remain prohibited from accessing the international market.” Nevertheless, Adelstone believes there could be a major inflection point on the horizon if the DEA shifts its definition of medical cannabis away from the Food and Drug Administration-approved pharmaceutical model and moves toward a more EU-style botanical flower framework. Such a change could open the door for DEA-registered producers to supply medical-use products to Europe’s fast-growing markets, particularly Germany. “In all of my conversations with international businesses, people want DEA marijuana for their medical programs because of its perceived high quality standards,” said Adelstone. He believes the botanical medical model may serve as a “middle ground” between strict pharmaceutical systems and the broader adult-use market. “The middle ground is between pharmaceuticals, food, and supplements,” he explained. As a plant, “cannabis doesn’t fit into those three FDA approval lanes, so if the FDA created a pathway under the [Food, Drug, and Cosmetic Act] for botanical substances — like cannabis flower or psychedelic mushrooms — that could be a good middle ground for establishing the type of medical marijuana system you see in Europe.” Adelstone added another possible middle ground would be for the DEA to allow registered bulk manufacturers to export flower to countries that will utilize it in their medical systems. “Over time, production and sale by DEA registrants may normalize marijuana flower as a medical product in the U.S.,” he said, “which could lead to a domestic medical program and possibly even the botanical pathway I mentioned.” Adelstone already is seeing rapid momentum as international supply chains form despite the lack of U.S. participation. “The supply chains are being developed, and the language is being written,” he said. Even if U.S. companies can’t yet take part in cross-border commerce, now is the time to align operations, documentation, and terminology with international norms. Doing so, Adelstone said, will allow American companies to “integrate more seamlessly” once permitted. He also sees a rare first-mover opportunity for DEA-registered operations to insert themselves into the international supply chain, especially for scientific and, potentially, medical purposes. “If I were an MSO with money, I would be trying to acquire a DEA registrant right now,” Adelstone suggested, urging companies to begin laying the groundwork for compliant trade and strategic business relationships. In addition, he pointed to growing investor interest in international markets, emphasizing that even though U.S. companies are restricted from exporting, they can participate abroad. “It’s not explicitly in the statutes, but under current judicial precedent, operating a foreign marijuana company or investing in one does not violate the Controlled Substances Act,” he explained. Canadian companies like Organigram and High Tide are capitalizing on this window of opportunity by investing in EU cannabis supply chains through mergers, acquisitions, and international partnerships. What’s at stake now The Global Cannabis Regulatory Summit marked a strategic convergence of regulators, scientists, and industry leaders determined to build the next phase of a global economy. For the United States, the message was clear: Reform cannot be delayed forever without consequences. Yet the story is not finished. With its deep bench of scientific expertise, entrepreneurial drive, and consumer demand, the U.S. still holds the potential to help shape international norms — if it chooses to engage. By embracing medical-first frameworks and aligning with pharma-grade standards already in place abroad, American operators can position themselves to reenter the global conversation not as bystanders, but as partners.The opportunity remains, but it requires foresight. Rather than being locked out, the nation that sparked the legalization movement could still help lead its future — provided it seizes the moment. ------------------------------ Charting the Next Steps for a Global Cannabis Market 1. Why is global cannabis alignment important? A unified framework ensures product safety, trade consistency, and credibility with international regulators. Fragmented systems slow growth and increase compliance risks. 2. What role do pharmaceutical-grade standards play? EU-GMP and GACP standards are setting the baseline for international trade. Without pharma-level protocols, companies can’t access most global medical markets. 3. How does U.S. rescheduling affect global trade? Moving cannabis to Schedule III could encourage U.S. pharma investment, but DEA restrictions mean only registrants will initially access export channels. 4. What actions should U.S. cannabis operators take now? Experts recommend aligning operations with GMP standards, building international partnerships, and preparing compliance systems to integrate seamlessly once trade opens. < Previous Next > Recent Reviews Cookies & Alt Sol "Ridgeline Lantz" Strain Review - Takoma Wellness Center Ridgeline Lantz, cultivated by Alt Sol and currently available at Takoma Wellness Center, exudes an impressive pedigree. With its origins... Watermelon Sugar, High: Fade Co.'s Live Resin Gummies Reviewed There's a running joke about Harry Styles' summer smash that the man himself has cheerfully leaned into: nobody is entirely sure what "watermelon sugar" is, only that it sounds fantastic and you want more of it. Fade Co. seems to have taken that ambiguity as a design brief. Their new live resin gummies don't just borrow the fruit - they capture the whole breezy, sun-warmed, slightly-too-good-to-analyze feeling the song trades in, then pack it ten to a tin... Platinum TK - Green Theory Dispensary Platinum TK is an indica-dominant hybrid from the skilled cultivators at Alt Sol that offers a robust and relaxing experience. Currently... 1 2 3 4 5

Everything about Champagne Diesel: effects, typical THC, lineage, and terpenes — plus hands-on product reviews and bud photos from Toker's Guide's DMV experts. < Back Champagne Diesel Strain Review Type Hybrid THC % 20% Dominant Terpene Energy Limonene Uplifted, Happy Overview Champagne Diesel is a balanced hybrid strain that combines the energetic qualities of Sour Diesel with the elegant, bubbly relaxation of Champagne. This strain is highly regarded for its ability to deliver a functional yet deeply satisfying experience, making it a favorite for those who enjoy a complex sensory profile alongside a versatile high. Effects Champagne Diesel is a balanced hybrid strain that offers a quick-onset cerebral buzz, enhancing focus, creativity, and mood, followed by a soothing physical relaxation that eases tension without heavy sedation. This versatile high makes it an excellent choice for daytime or early evening use, particularly for those looking to manage stress and fatigue while maintaining a clear and productive mindset. Its terpene profile is led by limonene, which provides citrus notes and mood-elevating effects; myrcene, which contributes to its underlying sweetness and promotes physical relaxation; and caryophyllene, which adds a touch of spice and may offer anti-inflammatory benefits. Together, these characteristics create a functional yet deeply satisfying experience that bridges the gap between pungent fuel flavors and sweet, floral notes. Positive Effects Side Effects Common Uses Relaxed 40% Happy 60% Euphoric 60% Uplifted 80% Talkative 0% Creative 60% Energetic 0% Focused 0% Giggly 0% Tingly 0% Hungry 0% Sleepy 0% stress, anxiety, cramps, inflammation, fibromyalgia Dry Mouth 20% Dry Eyes 0% Dizzy 0% Paranoid 0% Anxious 0% Hungry 0% Tingly 0% Sleepy 0% Appearance The buds of Champagne Diesel are visually striking, featuring a light green foliage that serves as a backdrop for a dense coating of frosty white trichomes. Bright orange pistils weave throughout the flowers, adding a vibrant contrast. The buds are typically medium-sized and possess a sticky, resinous texture. Aroma This strain offers a pungent and multifaceted scent. It leads with the classic, sharp chemical and diesel notes inherited from Sour Diesel, which are softened by a sweet, floral, and slightly fruity undertone from the Champagne lineage. Flavor On the palate, Champagne Diesel delivers a unique tasting experience. The inhale is dominated by a sourdough and fuel-like richness, while the exhale reveals a smooth, sweet, and effervescent finish reminiscent of sparkling wine and citrus. Lineage Champagne Diesel is a direct cross between the legendary Sativa-dominant Sour Diesel and the indica-leaning Champagne (also known as Champagne Kush). This pairing results in a hybrid that captures the cerebral stimulation of the former and the physical tranquility of the latter. Terpene Profile - Limonene: The most common terpene, providing citrus notes and mood-elevating effects. - Myrcene: Contributes to the underlying sweetness and promotes physical relaxation. - Caryophyllene: Adds a touch of spice and may offer anti-inflammatory benefits.Effects The high begins with a quick-onset cerebral buzz that enhances focus, creativity, and mood. As the initial stimulation plateaus, a soothing physical relaxation spreads through the limbs, easing tension without causing heavy sedation. It is an excellent choice for daytime or early evening use. Cultivation Preferences - Flowering Time: Approximately 8 to 10 weeks. - Yield: Moderate to high. - Climate: Thrives in temperate to warm Mediterranean climates and responds well to both indoor and outdoor setups with proper ventilation.Origin Champagne Diesel emerged from the North American breeding scene, where growers sought to refine the intense power of Diesel strains by crossing them with the more refined, flavorful profiles of "Champagne" varieties. Seed Suppliers Seeds and clones for Champagne Diesel can occasionally be found through specialty breeders and West Coast-based seed banks such as those carrying Dutch Passion or various Diesel-cross collections. Conclusion Champagne Diesel is a sophisticated hybrid that successfully bridges the gap between pungent fuel flavors and sweet, floral notes. Its balanced effects make it a versatile strain suitable for managing stress and fatigue while maintaining a clear and productive mindset. Previous Next

Everything about Purple Sage: effects, typical THC, lineage, and terpenes — plus hands-on product reviews and bud photos from Toker's Guide's DMV experts. < Back Purple Sage Strain Review Type Hybrid THC % 10% Dominant Terpene Energy NA Euphoric, Relaxed Overview Purple Sage is a rare hybrid cannabis strain that masterfully balances its diverse genetic heritage, offering a stimulating mental lift characteristic of its sativa roots alongside a powerful, pain-relieving body high typical of an indica. It is cherished by enthusiasts for its unique sensory profile and therapeutic versatility. Effects Purple Sage is a versatile hybrid strain that begins with an immediate cerebral rush, clearing the mind and boosting creativity before transitioning into a soothing physical relaxation. This balanced profile makes it highly effective for treating chronic pain, muscle spasms, and tension without causing immediate sedation, allowing for a functional yet relaxing experience. Its complex terpene profile is led by myrcene, which provides sedative and muscle-relaxing qualities, and caryophyllene, which offers anti-inflammatory benefits. Additionally, the presence of pinene supports mental focus and alertness, while limonene helps to elevate mood and reduce stress. These characteristics make Purple Sage an excellent choice for medical patients managing persistent pain and stress who still require a level of mental engagement. Positive Effects Side Effects Common Uses Relaxed 25% Happy 0% Euphoric 50% Uplifted 25% Talkative 0% Creative 37% Energetic 0% Focused 0% Giggly 0% Tingly 0% Hungry 0% Sleepy 25% pain, depression, anxiety, insomnia, muscle_spasms Dry Mouth 37% Dry Eyes 25% Dizzy 0% Paranoid 0% Anxious 0% Hungry 0% Tingly 0% Sleepy 25% Appearance The buds of Purple Sage are typically dense and spade-shaped, featuring a vibrant display of deep forest greens and striking purple hues. These colors are accentuated by thin, fiery orange hairs and a generous coating of milky-white trichomes that hint at its potency. Aroma This strain is renowned for its complex and inviting scent. It leads with a sweet, earthy base that is punctuated by sharp notes of spicy sandalwood and fresh pine, creating a pungent yet pleasant fragrance. Flavor The taste mirrors its aromatic complexity, providing a smooth smoke that tastes of sweet berries and spicy herbs. On the exhale, users often notice a lingering woody aftertaste with a subtle hint of citrus. Lineage Purple Sage is a cross between an unknown "Purple Mix" and the well-known SAGE (Sativa Afgani Genetic Equilibrium). This lineage results in a well-balanced hybrid that captures the best of both sativa and indica worlds. Terpene Profile - Myrcene: Contributes to the earthy aroma and provides sedative, muscle-relaxing effects. - Caryophyllene: Adds a spicy, peppery kick and offers anti-inflammatory benefits. - Pinene: Provides the distinct pine scent and helps with mental focus and alertness. - Limonene: Offers a touch of citrus and helps elevate mood and reduce stress.Effects The high begins with an immediate cerebral rush that clears the mind and boosts creativity. As the initial euphoria settles, a soothing physical relaxation spreads through the body, effectively treating chronic pain, muscle spasms, and tension without necessarily causing immediate sedation. Cultivation Preferences Purple Sage is considered a moderately difficult strain to grow, as it requires careful monitoring of humidity to protect its dense buds. - Flowering Time: Approximately 8 to 9 weeks. - Yield: Moderate to high, performing well in both indoor "Sea of Green" setups and sunny outdoor environments. - Growth Habit: The plants tend to grow medium-to-tall and may require pruning to ensure adequate light penetration to lower branches.Origin While its exact breeder remains somewhat of a mystery, Purple Sage is believed to have originated in the United States, emerging from the West Coast breeding scene where purple varieties and SAGE genetics are highly prized. Seed Suppliers Authentic seeds or clones for Purple Sage can occasionally be found through specialty boutiques and seed banks such as TH Seeds (the original creators of SAGE) or various West Coast nurseries that carry heritage hybrid genetics. Conclusion Purple Sage is an exceptional choice for those seeking a functional yet physically relaxing experience. Its stunning visual appeal, combined with its unique spicy-sweet flavor and balanced effects, makes it a standout cultivar for both recreational users and medical patients managing pain and stress. Previous Next

Cannabis retailers are enrolling sales staff in formal training programs like sommelier courses to help boost the sales of high-margin items. < Back Can sommelier training boost cannabis retail sales? Mar 4, 2026 Source: Chris Roberts MJbizDaily Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link In an effort to boost sales of high-margin items, some cannabis retailers are enrolling sales staff in formal training programs. Can sommelier training boost cannabis retail sales? is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs < Previous Next > Recent Reviews Cookies & Alt Sol "Ridgeline Lantz" Strain Review - Takoma Wellness Center Ridgeline Lantz, cultivated by Alt Sol and currently available at Takoma Wellness Center, exudes an impressive pedigree. With its origins... Watermelon Sugar, High: Fade Co.'s Live Resin Gummies Reviewed There's a running joke about Harry Styles' summer smash that the man himself has cheerfully leaned into: nobody is entirely sure what "watermelon sugar" is, only that it sounds fantastic and you want more of it. Fade Co. seems to have taken that ambiguity as a design brief. Their new live resin gummies don't just borrow the fruit - they capture the whole breezy, sun-warmed, slightly-too-good-to-analyze feeling the song trades in, then pack it ten to a tin... Platinum TK - Green Theory Dispensary Platinum TK is an indica-dominant hybrid from the skilled cultivators at Alt Sol that offers a robust and relaxing experience. Currently... 1 2 3 4 5

Gov. Greg Abbott is expected to issue an executive order to regulate THC in Texas, setting a minimum age of 21 for purchase and establishing rules similar to those for liquor sales, including ID checking, distance requirements from schools, labeling, and testing products for THC content, and fee increases for businesses. This comes after the Legislature failed to reach a deal on the matter. < Back Texas Governor Expected to Issue Hemp Executive Order with Age Limits and Testing Rules Sep 9, 2025 Source: Marijuana Moment Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Texas Governor Greg Abbott is stepping in where the legislature fell short, moving toward an executive order to regulate hemp-derived THC products across the Lone Star State. While some politicians pushed for a total ban, Abbott’s approach focuses on a strict regulatory framework. Expect to see a minimum age of 21 for all purchases, mandatory ID checks, and tighter rules on product testing and labeling. The proposed plan also suggests distance requirements from schools and potential fee increases for businesses. This shift could mirror how alcohol is sold, possibly limiting sales to specialized shops rather than general retailers. For the Texas cannabis community, this is a major win over the threat of a complete ban. Establishing clear ground rules for testing and labeling means safer, more reliable products for everyone. While the "liquor store model" might change where you shop, keeping these products legal and regulated ensures that enthusiasts can still access their favorite cannabinoids safely. It’s a significant step toward legitimacy for the industry in a historically tough state. < Previous Next > Recent Reviews Cookies & Alt Sol "Ridgeline Lantz" Strain Review - Takoma Wellness Center Ridgeline Lantz, cultivated by Alt Sol and currently available at Takoma Wellness Center, exudes an impressive pedigree. With its origins... Watermelon Sugar, High: Fade Co.'s Live Resin Gummies Reviewed There's a running joke about Harry Styles' summer smash that the man himself has cheerfully leaned into: nobody is entirely sure what "watermelon sugar" is, only that it sounds fantastic and you want more of it. Fade Co. seems to have taken that ambiguity as a design brief. Their new live resin gummies don't just borrow the fruit - they capture the whole breezy, sun-warmed, slightly-too-good-to-analyze feeling the song trades in, then pack it ten to a tin... Platinum TK - Green Theory Dispensary Platinum TK is an indica-dominant hybrid from the skilled cultivators at Alt Sol that offers a robust and relaxing experience. Currently... 1 2 3 4 5

Everything about Buddha Syrup: effects, typical THC, lineage, and terpenes — plus hands-on product reviews and bud photos from Toker's Guide's DMV experts. < Back Buddha Syrup Strain Review Type Indica THC % 18% Dominant Terpene Energy NA Relaxed, Sleepy Overview Buddha Syrup is a heavy-hitting, indica-dominant autoflowering cultivar developed by Buddha Seeds, specifically designed for those seeking a combination of sweet flavors and potent physical effects. Effects Buddha Syrup is a potent indica-dominant autoflowering strain known for delivering a powerful body high and deep relaxation, making it best suited for low-energy activities or nighttime use. Its effects are highly effective for those seeking medicinal relief, particularly for significantly increasing appetite and providing physical comfort through its heavy-hitting nature. The terpene profile is led by myrcene, which enhances the strain's sedative qualities and earthy base; caryophyllene, which contributes spicy ginger notes and potential anti-inflammatory benefits; and limonene, which adds a bright, fruity sweetness. Together, these characteristics make Buddha Syrup an excellent choice for medicinal users and connoisseurs looking for a flavorful strain that addresses appetite loss and promotes profound physical ease. Positive Effects Side Effects Common Uses Relaxed 100% Happy 0% Euphoric 0% Uplifted 0% Talkative 0% Creative 0% Energetic 0% Focused 0% Giggly 0% Tingly 0% Hungry 0% Sleepy 100% Unknown Dry Mouth 0% Dry Eyes 0% Dizzy 0% Paranoid 0% Anxious 0% Hungry 0% Tingly 0% Sleepy 100% Appearance The plants typically grow into a compact, bushy structure characteristic of indicas, producing dense, resin-rich buds that are often coated in a thick, sticky layer of white trichomes. Aroma The scent is intensely sweet and fruity, often described as reminiscent of medicinal syrup with a pungent, spicy undertone. Flavor On the palate, it offers a unique blend of sweet fruitiness layered with distinct notes of spicy ginger and tart elderberry, creating a complex and lingering taste. Lineage This strain is a result of a careful selection of indica genetics backcrossed with ruderalis to ensure stable autoflowering traits while maintaining the potency and growth characteristics of its indica ancestors. Terpene Profile - Myrcene: Contributes to the earthy base and enhances the sedative effects. - Caryophyllene: Provides the signature spicy ginger notes and potential anti-inflammatory benefits. - Limonene: Adds a bright, fruity sweetness to the overall aromatic profile.Effects Known for its heavy-hitting nature, Buddha Syrup delivers a powerful body high and deep relaxation. It is highly regarded for its ability to significantly increase appetite and provide relief for those seeking medicinal benefits from a potent smoke. Cultivation Preferences As an autoflowering variety, it is relatively easy to cultivate and transitions to bloom regardless of light cycle changes. - Flowering Time: Approximately 65 to 70 days from germination to harvest. - Yield: Moderate to high, performing exceptionally well in Sea of Green (SOG) setups. - Environment: Resilient and suitable for both indoor and outdoor cultivation, though it thrives in stable, warm climates.Origin The strain originated in Spain, created by the specialized breeders at Buddha Seeds. Seed Suppliers Genuine seeds can be sourced through Buddha Seeds, Seedsman, Alchimiaweb, and various international seed banks. Conclusion Buddha Syrup stands out as a flavorful and effective autoflowering strain. Its unique ginger and elderberry notes, combined with its therapeutic potency and ease of growth, make it an excellent choice for medicinal users and connoisseurs alike. Previous Next